Skip to main content

Table 2 Pharmacokinetics of fosmidomycin and clindamycin analysed by non-compartmental model in patients with acute uncomplicated falciparum malaria. Data are presented as median (95% C.I.) values.

From: Pharmacokinetics and pharmacodynamics of fosmidomycin monotherapy and combination therapy with clindamycin in the treatment of multidrug resistant falciparum malaria

Pharmacokinetic parameters Fosmidomycin monotherapy (N = 15) Fosmidomycin + Clindamycin (N = 18)
   Fosmidomycin Clindamycin
Cmax (μg/ml) 4.58 (2.32–6.77) 5.86 (2.79–12.52) 7.34 (4.88–12.73)
tmax (hr) 2 (1–4) 2 (1–4) 1 (1–2)
Ctrough-obs (μg/ml) 1.90 (0.92–2.99) 0.40 (0.0–2.01) 1.32 (0.39–3.42)
Cmin-ave (μg/ml) 1.47 (0.06–9.96) 1.06 (0.20–2.98) 0.17 (0.01–0.78)
Cmax-ave (μg/ml) 7.22 (1.52–15.84) 8.67 (4.21–14.23) 6.63 (3.96–9.52)
Css-ave (μg/ml) 3.74 (3.18–12.52) 2.93 (1.97–6.98) 1.91 (1.20–3.06)
Fluctuation 5.1 (1.6–47.6) 10.5 (3.6–40.3) 1.1 (0.7–1.6)
AUC0, t (μg.hr/ml) 22.91 (12.65–33.32) 35.00 (20.41–78.90) 31.80 (15.84–370.67)
AUC0,((μg.hr/ml) 29.7 (25.06–100.16) 39.13 (24.29–85.55) 31.91 (19.28–50.49)
λ Z (/hr 0.201 (0.06–0.48) 0.196 (0.107–0.308) 0.272 (0.156–0.464)
T1/2z (/hr) 3.4 (1.4–11.8) 3.5 (2.2–6.5) 2.6 (1.5–4.4)
VZ/F (l) 211.40 (96.84–823.04) 116.21 (69.94–267.45)a 67.50 (46.56–135-87)
CL/F (l/hr) 40.08 (11.97–47.18) 25.94 (10.74–38.13)b 18.77 (11.77–30.12)
  1. a = Statistically significant difference with monotherapy with p-value = 0.004
  2. b = Statistically significant difference with monotherapy with p-value < 0.0001